RedHill Biopharma Ltd. (RDHL) Form 6-K — Oct 19, 2026
RedHill Biopharma announced that its partner, the University of Oklahoma, received a $2.9 million, five-year grant from the National Cancer Institute to fund clinical trials of RedHill's opaganib in combination with CAR T-cell therapy in ultra-high-risk multiple myeloma. The grant funds a Phase 1b trial of up to 18 patients evaluating safety and dosing, followed by a Phase 2 trial of up to 21 additional patients seeking preliminary evidence of effectiveness. Preclinical mouse studies showed that blocking SPHK2 with opaganib helped CAR T cells stay active longer against myeloma.
Key figures
- Grant Amount Usd
- 2900000
- Phase2 Enrollment
- up to 21 additional patients
- Phase1b Enrollment
- up to 18 patients
- Grant Duration Years
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.